company background image
TLX

Telix PharmaceuticalsASX:TLX Stock Report

Market Cap

AU$1.6b

7D

-7.6%

1Y

237.3%

Updated

21 Oct, 2021

Data

Company Financials +
TLX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

TLX Overview

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Telix Pharmaceuticals
Historical stock prices
Current Share PriceAU$5.70
52 Week HighAU$1.61
52 Week LowAU$7.65
Beta2.42
1 Month Change-16.18%
3 Month Change8.16%
1 Year Change237.28%
3 Year Change551.43%
5 Year Changen/a
Change since IPO640.26%

Recent News & Updates

Shareholder Returns

TLXAU BiotechsAU Market
7D-7.6%0.4%1.5%
1Y237.3%2.5%21.1%

Return vs Industry: TLX exceeded the Australian Biotechs industry which returned 2.5% over the past year.

Return vs Market: TLX exceeded the Australian Market which returned 21.1% over the past year.

Price Volatility

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Beta2.42
Industry Beta1.63
Market Beta1

Stable Share Price: TLX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: TLX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aChris Behrenbruchhttps://www.telixpharma.com

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer).

Telix Pharmaceuticals Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
TLX fundamental statistics
Market CapAU$1.62b
Earnings (TTM)-AU$59.10m
Revenue (TTM)AU$6.52m

249.5x

P/S Ratio

-27.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLX income statement (TTM)
RevenueAU$6.52m
Cost of RevenueAU$1.98m
Gross ProfitAU$4.53m
ExpensesAU$63.63m
Earnings-AU$59.10m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin69.58%
Net Profit Margin-907.00%
Debt/Equity Ratio0.09%

How did TLX perform over the long term?

See historical performance and comparison

Valuation

Is Telix Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

46.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TLX (A$5.7) is trading below our estimate of fair value (A$10.57)

Significantly Below Fair Value: TLX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TLX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: TLX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLX is overvalued based on its PB Ratio (33.9x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is Telix Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

79.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: TLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TLX's is expected to become profitable in the next 3 years.

Revenue vs Market: TLX's revenue (75.4% per year) is forecast to grow faster than the Australian market (5.4% per year).

High Growth Revenue: TLX's revenue (75.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLX's Return on Equity is forecast to be low in 3 years time (16.4%).


Past Performance

How has Telix Pharmaceuticals performed over the past 5 years?

-52.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLX is currently unprofitable.

Growing Profit Margin: TLX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLX is unprofitable, and losses have increased over the past 5 years at a rate of 52.8% per year.

Accelerating Growth: Unable to compare TLX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: TLX has a negative Return on Equity (-123.3%), as it is currently unprofitable.


Financial Health

How is Telix Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: TLX's short term assets (A$70.3M) exceed its short term liabilities (A$22.3M).

Long Term Liabilities: TLX's short term assets (A$70.3M) exceed its long term liabilities (A$58.6M).


Debt to Equity History and Analysis

Debt Level: TLX's debt to equity ratio (0.09%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TLX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Telix Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Chris Behrenbruch (46 yo)

no data

Tenure

AU$421,493

Compensation

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD315.65K) is below average for companies of similar size in the Australian market ($USD1.42M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TLX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: TLX's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.3%.


Top Shareholders

Company Information

Telix Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Telix Pharmaceuticals Limited
  • Ticker: TLX
  • Exchange: ASX
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$1.625b
  • Shares outstanding: 285.07m
  • Website: https://www.telixpharma.com

Number of Employees


Location

  • Telix Pharmaceuticals Limited
  • 55 Flemington Road
  • Suite 401
  • North Melbourne
  • Victoria
  • 3051
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:21
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.